NO20053304L - NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse - Google Patents

NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Info

Publication number
NO20053304L
NO20053304L NO20053304A NO20053304A NO20053304L NO 20053304 L NO20053304 L NO 20053304L NO 20053304 A NO20053304 A NO 20053304A NO 20053304 A NO20053304 A NO 20053304A NO 20053304 L NO20053304 L NO 20053304L
Authority
NO
Norway
Prior art keywords
human
nogo
binding molecule
binding molecules
pharmaceutical use
Prior art date
Application number
NO20053304A
Other languages
English (en)
Other versions
NO20053304D0 (no
Inventor
Martin E Schwab
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schnell
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Univ Zuerich Prorektorat Forsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich Prorektorat Forsc filed Critical Univ Zuerich Prorektorat Forsc
Publication of NO20053304D0 publication Critical patent/NO20053304D0/no
Publication of NO20053304L publication Critical patent/NO20053304L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Denne oppfinnelse vedrører molekyler, slik som for eksempel monoklonale antistoffer eller Fab-fragmenter av dem, som er i stand til å binde seg til det humane NogoA polypeptidet eller humant NiG eller humant NiG- eller humant NogoA-623-640 med en dissosiasjonskonstant som er < 1000 nM; polynukleotider som koder for et slikt bindingsmolekyl; en ekspresjonsvektor som omfatter slike polyonukleotider; anvendelsen av et slikt bindingsmolekyl i behandlingen av nervereparasjon; en farmasøytisk sammensetning som omfatter et slikt bindingsmolekyl; og en fremgangsmåte for behandling av sykdommer assosiert med nervereparasjon.
NO20053304A 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse NO20053304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (2)

Publication Number Publication Date
NO20053304D0 NO20053304D0 (no) 2005-07-06
NO20053304L true NO20053304L (no) 2005-09-07

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053304A NO20053304L (no) 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Country Status (25)

Country Link
US (2) US7785593B2 (no)
EP (1) EP1572745B1 (no)
JP (1) JP4504200B2 (no)
KR (1) KR101215801B1 (no)
CN (1) CN100384877C (no)
AT (1) ATE475671T1 (no)
AU (1) AU2003289998B2 (no)
BR (1) BR0317161A (no)
CA (1) CA2509068C (no)
CY (1) CY1110848T1 (no)
DE (1) DE60333585D1 (no)
DK (1) DK1572745T3 (no)
EC (1) ECSP055849A (no)
ES (1) ES2349293T3 (no)
GB (1) GB0228832D0 (no)
HK (1) HK1084676A1 (no)
IL (1) IL169018A (no)
MX (1) MXPA05006265A (no)
NO (1) NO20053304L (no)
PL (1) PL210720B1 (no)
PT (1) PT1572745E (no)
RU (1) RU2350623C2 (no)
SI (1) SI1572745T1 (no)
WO (1) WO2004052932A2 (no)
ZA (1) ZA200504522B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
AU2006265276B2 (en) * 2005-07-05 2011-10-13 Glaxo Group Limited Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3007556B1 (en) * 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
EP4048692A2 (en) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Novel anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
HU219537B (hu) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
AU774367C (en) 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ES2341842T3 (es) 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausruestung Fuer Zelt
WO2003048083A2 (en) * 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
US20110059110A1 (en) 2011-03-10
IL169018A (en) 2012-07-31
PT1572745E (pt) 2010-10-21
US7785593B2 (en) 2010-08-31
RU2005121669A (ru) 2007-01-20
PL210720B1 (pl) 2012-02-29
JP4504200B2 (ja) 2010-07-14
JP2006523087A (ja) 2006-10-12
CA2509068C (en) 2012-02-07
WO2004052932A3 (en) 2004-10-21
ATE475671T1 (de) 2010-08-15
ES2349293T3 (es) 2010-12-29
ECSP055849A (es) 2005-09-20
PL377506A1 (pl) 2006-02-06
BR0317161A (pt) 2005-11-01
MXPA05006265A (es) 2005-12-05
RU2350623C2 (ru) 2009-03-27
DK1572745T3 (da) 2010-10-25
DE60333585D1 (de) 2010-09-09
NO20053304D0 (no) 2005-07-06
ZA200504522B (en) 2006-03-29
KR101215801B1 (ko) 2012-12-26
CN1747971A (zh) 2006-03-15
CN100384877C (zh) 2008-04-30
SI1572745T1 (sl) 2010-12-31
HK1084676A1 (en) 2006-08-04
US8535666B2 (en) 2013-09-17
EP1572745B1 (en) 2010-07-28
CA2509068A1 (en) 2004-06-24
GB0228832D0 (en) 2003-01-15
KR20050095768A (ko) 2005-09-30
AU2003289998B2 (en) 2008-02-14
WO2004052932A2 (en) 2004-06-24
CY1110848T1 (el) 2015-06-10
US20060183678A1 (en) 2006-08-17
EP1572745A2 (en) 2005-09-14
AU2003289998A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
EA200700136A1 (ru) Анти-cd154-антитела
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
TW200635946A (en) Binding proteins specific for human matriptase
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE602006020333D1 (de) Multimere fc-rezeptor-polypeptide
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2004032832A3 (en) Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
Cozma Determination of Primary Structure and Affinity Characterization of Naturally Occurring β-Amyloid Autoantibodies
Cai et al. Identification of a cysteine-histidine thioether bridge bond in functional units d, e and f of β</inf> c<//inf>-haemocyanin of the gastropod Helix pomatia
CY1115920T1 (el) Αντι-gm-csf αντισωματα και χρησεις αυτων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application